Diagnosis and Management of Ectopic Pregnancy

1Introduction, Epidemiology, and Risk Factors

• GPPDefinition: An ectopic pregnancy is any pregnancy implanted outside of the endometrial cavity.
  • The guideline covers tubal, cervical, caesarean scar, interstitial, cornual, ovarian, abdominal, and heterotopic pregnancies.
  • Pregnancy of unknown location (PUL) is excluded from this guideline and is managed under NICE guidelines.
• GPPEpidemiology and Incidence (UK):
  • UK incidence is approximately 11 per 1000 pregnancies (~11,000 cases diagnosed annually).
  • Incidence among women attending early pregnancy units (EPUs) is 2% to 3%.
  • Case fatality rates have decreased over recent years, reflecting earlier diagnosis and treatment.
• GPPRisk Factors:
  • Key risk factors include tubal damage (following surgery or infection), smoking, and in vitro fertilisation (IVF).
  • Clinical Note: The majority of women presenting with an ectopic pregnancy have no identifiable risk factors.
• MechanismPathophysiology of Environmental and Infectious Risk Factors:
  • Cotinine (smoking) exposure increases Fallopian tube PROKR1 (Prokineticin Receptor 1) expression, mediated via nicotinic acetylcholine receptors (AChRa-7), providing a direct molecular mechanism linking smoking to tubal ectopic pregnancy.
  • Chlamydia trachomatis infection increases Fallopian tube PROKR2 expression via Toll-like Receptor 2 (TLR2) and NF-κB pathways, altering the tubal microenvironment and predisposing to ectopic implantation.

2Diagnosis of Tubal Ectopic Pregnancy

Diagnostic criteria, ultrasound findings, and biochemical markers used to identify and plan the management of tubal ectopic pregnancies.

• BTransvaginal ultrasound (TVS/TVUS) is the diagnostic tool of choice for tubal ectopic pregnancy.
  • TVS has a reported sensitivity of 87.0% to 99.0% and specificity of 94.0% to 99.9%.
  • The majority of ectopic pregnancies are visualised on the initial scan; those not seen are initially classified as PUL.
• DTubal ectopic pregnancies should be positively identified, if possible, by visualising an adnexal mass that moves separate to the ovary.
• GPPLaparoscopy Status: Laparoscopy is no longer the gold standard for diagnosis.
  • False-negative laparoscopy rates of 3.0% to 4.5% are reported when performed too early in the development of an ectopic pregnancy.
• GPPEndometrial Cavity and 'Pseudosac' Considerations:
  • There is no specific endometrial appearance or thickness that reliably diagnoses a tubal ectopic pregnancy.
  • An intrauterine fluid collection ('pseudosac') is seen in up to 20% of ectopic pregnancies and must not be confused with an early intrauterine pregnancy (IUP).
  • Intradecidual sign: Fluid collection with an echogenic rim located within a markedly thickened decidua on one side of the uterine cavity (indicates early IUP).
  • Double decidual sign: Intrauterine fluid collection surrounded by two concentric echogenic rings (indicates early IUP).
  • Probability Rule: A woman with a positive pregnancy test, an intrauterine smooth-walled anechoic cystic structure, and no adnexal mass has a 99.98% probability of an IUP and only a 0.02% probability of an ectopic pregnancy.
• GPPFree Fluid Assessment:
  • A small amount of anechoic fluid in the pouch of Douglas is non-specific and can be found in both IUP and ectopic pregnancies.
  • Echogenic fluid is reported in 28% to 56% of ectopic pregnancies; it may signify tubal rupture or blood leaking from the fimbrial end.
• BA serum progesterone level is not useful in predicting ectopic pregnancy.
• CA serum beta-human chorionic gonadotrophin (b-hCG) level is useful for planning the management of an ultrasound-visualised ectopic pregnancy.
  • A single b-hCG level cannot be used in isolation to predict or rule out an ectopic pregnancy.
  • Caution: A single low serum b-hCG level (e.g. <1000 iu/l) does not rule out an ectopic pregnancy.
  • The initial serum b-hCG level is a key prognostic indicator for the success of conservative (expectant and medical) management.

3Diagnosis of Non-Tubal (Atypical) Ectopic Pregnancies

Diagnostic criteria, ultrasound features, and biochemical requirements for rare and atypical ectopic implantation sites.

• DCervical Pregnancy: Implantation within the endocervical canal below the internal os.
  • Accounts for less than 1% of all ectopic gestations.
  • Ultrasound criteria: Empty uterine cavity, barrel-shaped cervix, gestational sac present below the level of the internal cervical os, absence of the 'sliding sign', and blood flow around the gestational sac demonstrated using colour Doppler.
  • The Sliding Sign: In a miscarriage, the gestational sac slides against the endocervical canal when pressure is applied with the probe. In a cervical ectopic, the sac is implanted and does not slide.
  • A single serum b-hCG should be performed at diagnosis to help with management planning (levels >10,000 iu/l are associated with medical treatment failure).
• DCaesarean Scar Pregnancy (CSP): Implantation within the myometrium of a previous lower segment caesarean section scar.
  • Prevalence is approximately 1 in 2000 pregnancies; misdiagnosis rate is 13% (often mistaken for intrauterine or cervical pregnancies).
  • Ultrasound criteria: Empty uterine cavity, gestational sac or solid mass of trophoblast located anteriorly at the level of the internal os embedded at the scar site, thin or absent myometrium between the sac and bladder, empty endocervical canal, and prominent Doppler circulation.
  • MRI can be used as a second-line investigation if the diagnosis is equivocal and local expertise is available.
  • No biochemical investigations are needed routinely for diagnosis, but baseline b-hCG is useful prior to monitoring.
  • All non-emergency cases of suspected scar pregnancy should be referred to a regional centre to confirm the diagnosis.
• 3Vial et al. Classification of Caesarean Scar Pregnancy (CSP):
  • Type 1 (Endogenous): Progresses into the uterine cavity as the sac grows; has potential to reach a viable gestational age but carries a high risk of massive bleeding from the implantation site.
  • Type 2 (Exogenous): Progresses deeper towards the serosal surface of the uterus; carries a high risk of first-trimester uterine rupture and severe haemorrhage.
• DInterstitial Pregnancy: Implantation in the intramural segment of the fallopian tube (1.0% to 6.3% of ectopics).
  • Ultrasound criteria: Empty uterine cavity, products of conception/gestational sac located laterally in the interstitial part of the tube, sac surrounded by less than 5 mm of myometrium in all imaging planes, and presence of the 'interstitial line sign'.
  • The 'interstitial line sign' (thin echogenic line extending from the central uterine cavity echo to the periphery of the interstitial sac) has a sensitivity of 80% and specificity of 98%.
  • 3D ultrasound should be used where available to confirm 2D findings and avoid misdiagnosis with early intrauterine or angular pregnancy.
  • MRI shows a gestational sac-like structure lateral to the cornua with an intact junctional zone between the uterine cavity and the sac.
  • A single serum b-hCG should be performed at diagnosis (repeat in 48 hours is optional for small, stable cases).
• DCornual Pregnancy: Implantation in one horn of a congenitally abnormal uterus (e.g. bicornuate or unicornuate uterus).
  • Extremely rare, with an estimated incidence of 1 in 76,000 pregnancies. Often incorrectly used synonymously with 'interstitial pregnancy'.
  • Ultrasound criteria: Visualisation of a single interstitial portion of the fallopian tube in the main uterine body, gestational sac/products of conception seen mobile and separate from the uterus and completely surrounded by myometrium, and a vascular pedicle adjoining the sac to the unicornuate uterus.
  • A single serum b-hCG should be performed at diagnosis (repeat in 48 hours is optional).
• DOvarian Pregnancy: Implantation of the gestational sac within the ovary.
  • Ultrasound findings: Wide echogenic ring with an internal anechoic area on the ovary, negative sliding organ sign (inability to separate the sac from the ovary using gentle palpation), and identification of the corpus luteum as a separate structure.
  • Ruptured ovarian pregnancy presents as a complex echogenic adnexal mass with free fluid in the pouch of Douglas.
  • Must be distinguished from corpus luteal cysts, tubal ectopic adhered to the ovary, a second corpus luteum, and ovarian germ cell tumours. Diagnosis is confirmed surgically and histologically (Spiegelberg Criteria).
  • A single serum b-hCG should be performed at diagnosis (repeat in 48 hours is optional).
• DAbdominal Pregnancy: Implantation within the peritoneal cavity, excluding tubal, ovarian, or intraligamentary sites.
  • Gerli et al. Ultrasound Criteria: Absence of an intrauterine gestational sac; absence of both an evident dilated tube and a complex adnexal mass; a gestational cavity surrounded by loops of bowel and separated from them by peritoneum; and wide mobility (fluctuation) of the sac with probe pressure.
  • MRI is a critical diagnostic adjunct in advanced abdominal pregnancy to confirm diagnosis, identify placental implantation over vital structures, and guide perioperative planning.
  • Diagnosis relies on a high index of suspicion based on elevated serum b-hCG combined with ultrasound findings.
• DHeterotopic Pregnancy: Coexistence of an intrauterine pregnancy (IUP) and an ectopic pregnancy.
  • Incidence is rare in natural conception (1 in 30,000) but rises significantly to 1-3% after Assisted Reproductive Technology (ART) / IVF.
  • Consider in all women presenting after ART, women with an IUP presenting with persistent pelvic pain, or women with a persistently raised b-hCG level following miscarriage or termination.
  • Serum b-hCG level is of limited value in diagnosing heterotopic pregnancy.

4Management of Tubal Ectopic Pregnancy

Surgical, pharmacological, and expectant management pathways for tubal ectopic pregnancies, including patient selection and follow-up protocols.

• ASurgical Approach: A laparoscopic surgical approach is preferable to an open approach (laparotomy).
  • Laparoscopy offers shorter operation times, less intraoperative blood loss, shorter hospital stays, lower costs, lower analgesic requirements, and less adhesion formation.
  • Subsequent successful pregnancy rates (long-term fertility benefits) do not differ significantly between laparoscopy and laparotomy.
• BSalpingectomy vs. Salpingotomy:
  • In the presence of a healthy contralateral tube, salpingectomy should be performed in preference to salpingotomy.
  • Salpingotomy does not significantly improve fertility prospects compared with salpingectomy in women with a healthy contralateral tube.
  • The European Surgery in Ectopic Pregnancy (ESEP) study showed no significant difference in cumulative ongoing pregnancy rates between salpingotomy (60.7%) and salpingectomy (56.2%) when the contralateral tube is healthy.
  • Persistent trophoblast is significantly higher after salpingotomy (7% vs. <1% in salpingectomy; RR 15.0).
  • Repeat ectopic pregnancy rates are 8% after salpingotomy compared to 5% after salpingectomy.
• CIndications for Salpingotomy:
  • Salpingotomy should be considered in women with a history of fertility-reducing factors (previous ectopic pregnancy, contralateral tubal damage, previous abdominal surgery, or previous pelvic inflammatory disease).
  • In these high-risk women, subsequent intrauterine pregnancy rates are higher with salpingotomy compared to salpingectomy (75% vs. 40%).
• GPPCounselling and Follow-up for Salpingotomy:
  • Women must be informed of the risk of persistent trophoblast and the absolute necessity of follow-up serum b-hCG monitoring.
  • Counsel patients on the small risk of requiring further treatment, such as systemic methotrexate or completion salpingectomy.
  • NICE Follow-up Protocol: Measure serum b-hCG 7 days after surgery, and then weekly until a negative result (<15 IU/L) is obtained.
• BSystemic Methotrexate (MTX): May be offered to suitable women with a tubal ectopic pregnancy.
  • Caution: MTX should never be given at the first visit unless the diagnosis of ectopic pregnancy is absolutely clear and a viable intrauterine pregnancy has been definitively excluded.
  • Prophylactic MTX administered at the time of laparoscopic salpingotomy significantly reduces the rate of persistent trophoblast (1.9% vs. 14.5% with salpingotomy alone).
• BExpectant Management: A safe and viable option for highly selected, clinically stable, symptom-free women.
  • Requires an ultrasound-confirmed diagnosis of ectopic pregnancy and a decreasing b-hCG level that is initially less than 1500 IU/L.
  • Selection Criteria (Prospective Data): Clinical stability, no abdominal pain, no significant haemoperitoneum on ultrasound, ectopic mass < 30 mm mean diameter, no embryonic cardiac activity, and initial serum b-hCG < 1500 iu/l.
  • Follow-up Protocol: Monitor until serum b-hCG is < 20 iu/l, with repeat tests scheduled every 2 to 7 days.
  • Discontinuation Criteria: Intervene if the patient requests to opt out, develops significant pain, or if serum b-hCG shows a sustained increase or rises to > 2000 iu/l.
  • Pretreatment b-hCG Ratio Predictor: A ratio of < 0.8 (b-hCG at 48 hours / b-hCG at 0 hours) strongly predicts successful expectant management (overall success ~72%).
  • Methotrexate vs. Expectant Management: In women with low or plateauing b-hCG (< 1500 iu/l for ectopic; < 2000 iu/l for PUL), there is no significant difference in primary treatment success between single-dose MTX (76%) and expectant management (59%).

5Management of Non-Tubal (Atypical) Ectopic Pregnancies

Site-specific surgical, medical, and conservative management options for atypical ectopic pregnancies.

• DCervical Pregnancy Management:
  • Medical management with methotrexate can be considered as a primary conservative option (estimated efficacy ~91%, though often requires adjunctive local injection or surgical debulking).
  • Surgical methods have high failure rates and should be reserved strictly for women with life-threatening bleeding.
  • Traditional dilatation and curettage (D&C) carries a high risk of severe bleeding necessitating emergency hysterectomy; restrict its use to cases where alternative measures are unsuitable.
  • Predictors of successful conservative management: Gestational age < 12+0 weeks, absence of fetal cardiac activity, and lower baseline serum b-hCG levels.
  • Risk factors for primary failure of systemic MTX: Gestational age > 9+0 weeks, b-hCG > 10,000 iu/l, crown-rump length (CRL) > 10 mm, and presence of fetal cardiac activity.
  • Adjunctive methods to control haemorrhage: Uterine artery ligation, uterine artery embolisation (UAE), cerclage, or balloon tamponade. UAE complications include infection, uterine infarction, sciatic nerve injury, and necrosis of the bladder or rectum.
• DCaesarean Scar Pregnancy (CSP) Management:
  • Women must be counselled that these pregnancies are associated with severe maternal morbidity and mortality (high risk of rupture, severe haemorrhage, and early placenta accreta spectrum).
  • Continuing pregnancy carries extreme risks of emergency hysterectomy (22 out of 35 cases in literature, ranging from 15 to 38 weeks) due to severe haemorrhage and morbidly adherent placenta (MAP).
  • Medical and surgical interventions (with or without additional haemostatic measures) should be considered in the first trimester. Current literature supports a surgical rather than medical approach as the most effective.
  • Medical options: Primary medical treatment consists of methotrexate, administered either via local ultrasound-guided injection into the gestational sac (more effective) or systemically. Retained trophoblast poses a risk of haemorrhage as vascular placental tissue degenerates.
  • Surgical options: Evacuation techniques (suction evacuation or hysteroscopic resection) or excisional techniques (open, laparoscopic, or transvaginal excision allowing scar repair).
  • Expectant management: Suitable only for small, nonviable scar pregnancies, or if the pregnancy is partially implanted and growing into the uterine cavity and the woman declines termination.
  • Ongoing second-trimester CSP: High risk of maternal morbidity and hysterectomy; requires a multidisciplinary care package for MAP.
• DInterstitial Pregnancy Management:
  • Nonsurgical management is acceptable for stable interstitial pregnancies.
  • Expectant management is only suitable for women with low or significantly falling b-hCG levels (successful conservative cases had mean hCG of ~3216 iu/l vs. failed cases at ~15,900 iu/l).
  • Pharmacological approach using methotrexate (local or systemic) is effective. Systemic MTX (50 mg/m² IM) or single-dose IV MTX with oral folinic acid rescue (91% success). Local US-guided intrasaccular injection of 25 mg MTX +/- KCl has a 91% success rate and fewer side effects.
  • Surgical options: Laparoscopic cornual resection or salpingotomy. Laparoscopic haemostasis can be facilitated by electrocauterisation, endoloop application, encircling/purse-string sutures, or highly diluted vasopressin (20 U in 1000 ml saline; 150-250 ml injected below the pregnancy).
  • Alternative surgical techniques: Hysteroscopic resection under laparoscopic or ultrasound guidance.
• DCornual Pregnancy Management:
  • Cornual pregnancies should be managed by excision of the rudimentary horn via laparoscopy or laparotomy to prevent recurrence and life-threatening rupture.
  • Laparoscopic technique: Involves excision of the fibrous band attaching the rudimentary horn to the unicornuate uterus, followed by removal of the horn through a secondary port.
  • Preoperative preparation: Methotrexate and potassium chloride (KCl) local injections can be used prior to surgical excision.
  • Anatomical Caution: Surgeons must remain highly vigilant for urinary tract anomalies, which are frequently associated with unicornuate uteri.
• DOvarian Pregnancy Management:
  • Definitive surgical treatment is preferred if laparoscopy is required to make the diagnosis.
  • Surgical technique: Blunt enucleation of gestational products is preferred to minimise damage to surrounding ovarian tissue. Wedge resection is indicated for large ectopic masses. Oophorectomy is reserved for cases with coexisting ipsilateral pathology or uncontrollable haemorrhage.
  • Systemic methotrexate can be used if surgical risk is high, or postoperatively for persistent residual trophoblast / persistently raised b-hCG. Primary treatment with MTX alone has a high failure rate (up to 40%).
• DAbdominal Pregnancy Management:
  • Early abdominal pregnancy: Laparoscopic removal is safe and effective if the implantation site does not involve a highly vascular area. Systemic MTX combined with ultrasound-guided fetocide is a possible alternative.
  • Advanced abdominal pregnancy must be managed by laparotomy. The surgical incision must be planned to avoid incising the placenta.
  • Placental management: The placenta may be left in situ to await spontaneous resorption if its vascular attachment involves major vessels or vital structures. Leaving the placenta in situ is associated with significant morbidity (ileus, bowel obstruction, fistula, haemorrhage, peritonitis) but has lower mortality than forced removal.
• BHeterotopic Pregnancy Management:
  • The viable intrauterine pregnancy (IUP) must always be actively considered in the management plan.
  • Systemic methotrexate is contraindicated in heterotopic pregnancy unless the IUP is nonviable or the woman does not wish to continue with it.
  • Local treatment options for clinically stable women: Local injection of potassium chloride (KCl) or hyperosmolar glucose combined with aspiration of the sac contents. Ultrasound follow-up is mandatory to monitor resolution (serial b-hCG is unusable).
  • Surgical removal of the ectopic pregnancy: The absolute method of choice for haemodynamically unstable women, and a safe option for stable women. Avoid uterine manipulation/cannulation during laparoscopy.
  • Expectant management is an option only when ultrasound findings confirm the ectopic pregnancy is nonviable.

6Single-Dose Methotrexate Protocol and Contraindications

Standardised clinical protocol, monitoring schedule, predictors of success, and absolute/relative contraindications for single-dose intramuscular methotrexate therapy.

• ProtocolThe standard single-dose regimen utilizes intramuscular methotrexate at a dose of 50 mg/m².
  • Day 1 baseline investigations must be performed prior to administration: Serum b-hCG, Urea & Electrolytes (U&E), Liver Function Tests (LFTs), Full Blood Count (FBC), and Blood Group.
  • Serial serum b-hCG levels are measured on Day 4 and Day 7 following administration.
  • The percentage change in b-hCG is calculated between Day 4 and Day 7 to determine subsequent management.
• ThresholdManagement pathway based on Day 4 to Day 7 b-hCG decrease:
  • Decrease < 15%: Perform a repeat transvaginal scan (TVS) to exclude ectopic fetal cardiac activity and significant haemoperitoneum, and administer a second dose of methotrexate (50 mg/m²) if the patient still meets the criteria.
  • Decrease ≥ 15%: Repeat serum b-hCG weekly until levels decline to < 15 IU/L.
  • Overall success rate of single-dose MTX ranges from 65% to 95%, with 3% to 27% of women requiring a second dose.
• GPPPatient Advice During Treatment:
  • Patients must strictly avoid alcohol and folate-containing vitamins during treatment.
• EvidenceAdverse Effects of Methotrexate:
  • Most common side effects: Excessive flatulence and bloating (due to intestinal gas), transient mild elevation in liver enzymes, and stomatitis.
  • Severe/Systemic risks: Bone marrow suppression, pulmonary fibrosis, nonspecific pneumonitis, liver cirrhosis, renal failure, and gastric ulceration.
• AbsoluteAbsolute Contraindications to Methotrexate:
  • Haemodynamic instability.
  • Presence of an intrauterine pregnancy (coexisting heterotopic pregnancy or diagnostic uncertainty).
  • Breastfeeding (due to excretion of methotrexate into breast milk).
  • Known hypersensitivity or sensitivity to methotrexate.
• MedicalPre-existing Organ Dysfunction and Systemic Diseases (Contraindications):
  • Chronic liver disease (methotrexate is hepatotoxic).
  • Pre-existing blood dyscrasias (risk of severe bone marrow suppression).
  • Active pulmonary disease.
  • Immunodeficiency states.
  • Active peptic ulcer disease.
• RelativeRelative/Logistical Contraindications:
  • Inability or unwillingness of the patient to comply with the rigorous follow-up protocol.

7Rhesus D Prophylaxis and Long-Term Fertility Prospects

Guidelines on anti-D administration and counseling regarding future reproductive outcomes, ovarian reserve, and conception timelines.

• DRhesus D Prophylaxis Indications:
  • Offer anti-D prophylaxis to all RhD-negative women who undergo surgical removal of an ectopic pregnancy, or where bleeding is repeated, heavy, or associated with abdominal pain.
  • Alloimmunisation has been documented following ectopic pregnancy; approximately 25% of ruptured tubal ectopic pregnancies are associated with a significant feto-maternal haemorrhage.
  • Surgical management carries a higher risk of sensitisation due to mechanical mixing of fetal and maternal blood.
• NICENICE vs. BCSH Guidance Conflict on Anti-D:
  • NICE recommends offering anti-D prophylaxis only to women undergoing surgical management of ectopic pregnancy, as the risk of feto-maternal haemorrhage is low in medical and expectant management.
  • Note: This recommendation is contrary to the British Committee for Standards in Haematology (BCSH) guidance, which is more liberal.
• DLong-Term Fertility Prospects (No Prior Subfertility):
  • In women without a history of subfertility or tubal pathology, the management method (expectant, medical, or surgical) does not affect future fertility rates, recurrent ectopic pregnancy risk, or tubal patency rates.
  • The long-term recurrent ectopic pregnancy rate across all methods is approximately 18.5%.
  • Hysterosalpingography (HSG) confirms no difference in ipsilateral tubal patency (for expectant/medical) or contralateral tubal patency (across all methods).
• CLong-Term Fertility Prospects (With Prior Subfertility):
  • In women with a history of subfertility, expectant or medical management is associated with improved reproductive outcomes compared with radical surgery.
  • Radical surgery (salpingectomy) in women with prior subfertility or age >35 years is associated with lower subsequent intrauterine pregnancy rates.
• DOvarian Reserve and Specialized Management Outcomes:
  • Methotrexate treatment for tubal ectopic pregnancy has no adverse effect on ovarian reserve (no significant changes in AMH, antral follicle count, or ovarian responsiveness).
  • Caution: If IVF/fertility treatment is restarted within 180 days of methotrexate, oocyte yield may be lower.
  • Subsequent live births have been reported after uterine artery embolisation (UAE) and systemic methotrexate for non-tubal ectopic pregnancies (up to 83% conception and 58% live birth rates).
  • Future fertility prospects are good following laparoscopic management of ovarian pregnancies (up to 100% subsequent conception and 83% live birth rates).
• DConception Timeline Post-Methotrexate:
  • Women treated with methotrexate must wait at least 3 months before attempting to conceive again.
  • This delay is necessary due to the persistence of methotrexate in tissues and potential teratogenic risks.
  • Conception within 3 months of methotrexate exposure is associated with a higher major malformation rate, but is NOT an absolute indication for termination of pregnancy.